Cognition Therapeutics Inc. Updates on Alzheimer’s Disease Research

Cognition Therapeutics, Inc., a biopharmaceutical company headquartered in Pittsburgh, United States, continues to make strides in its mission to combat cognitive decline associated with Alzheimer’s disease and other degenerative brain disorders. The company, which operates globally, focuses on the discovery and development of small molecule therapeutics aimed at targeting toxic proteins implicated in these conditions.

As of July 16, 2025, Cognition Therapeutics is listed on the Nasdaq stock exchange, with its shares trading at a close price of $0.568 on July 14, 2025. The company’s market capitalization stands at approximately $43,380,000 USD. Over the past year, the stock has experienced significant volatility, reaching a 52-week high of $2.535 on July 25, 2024, and a 52-week low of $0.222 on May 27, 2025. The price-to-earnings ratio is currently at -0.952906, reflecting the company’s ongoing investment in research and development.

Cognition Therapeutics serves a global customer base through its official website, www.cogrx.com , and maintains a strong presence in the health care sector. The company’s innovative approach to addressing the challenges of Alzheimer’s disease and related conditions positions it as a key player in the biopharmaceutical industry.

As the company progresses with its research initiatives, stakeholders and investors are closely monitoring its developments, anticipating breakthroughs that could significantly impact the treatment landscape for cognitive decline.